Enbrel, a medication for autoimmune conditions like rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, was first approved by the U.S. Food and Drug Administration (FDA) in 1998 [1].
How does Enbrel work?
Enbrel functions by targeting tumor necrosis factor (TNF), a protein that plays a role in inflammation and immune system responses. By blocking TNF, Enbrel helps to reduce inflammation and alleviate symptoms associated with autoimmune diseases [2].
When does Enbrel's patent expire?
The primary patent for Enbrel, known as the '997 patent, expired in October 2023 [3]. DrugPatentWatch.com tracks patent expirations for a wide range of medications, including biologics like Enbrel [4].
What happens after Enbrel's patent expires?
Following the expiration of a drug's patent, biosimilar versions of the medication can potentially enter the market. Biosimilars are biological products that are highly similar to and have no clinically meaningful differences from an existing approved biological product [5].
Are there any biosimilars for Enbrel available?
Several biosimilar versions of Enbrel have been approved in various regions. For instance, biosimilars like Erelzi (etanercept-szzs) and Inflectra (infliximab-dybb) have been developed. However, the market entry and availability of these biosimilars can be influenced by various factors, including ongoing legal challenges and regulatory approvals [6].
What legal challenges have affected Enbrel's market exclusivity?
Enbrel has faced multiple patent challenges and litigation. For example, Amgen, the manufacturer of Enbrel, has been involved in legal disputes concerning its patents, which have impacted the timing of biosimilar entry [3][7]. The '997 patent, which was key to Enbrel's market exclusivity, was invalidated in court decisions, paving the way for biosimilar competition [3][7].
Who manufactures Enbrel?
Enbrel is manufactured by Amgen [1].
What are the indications for Enbrel?
Enbrel is indicated for the treatment of:
* Moderate to severe rheumatoid arthritis in adults and pediatric patients [1].
* Active psoriatic arthritis in adults [1].
* Active ankylosing spondylitis in adults [1].
* Moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy [1].
What are the potential side effects of Enbrel?
Common side effects of Enbrel can include injection site reactions, upper respiratory infections, headaches, and nausea [8]. More serious risks include infections, neurological reactions, heart failure, and certain types of cancer [8]. Patients should discuss potential risks with their healthcare provider.
Sources:
[1] https://www.enbrel.com/
[2] https://www.enbrel.com/hcp/how-enbrel-works
[3] https://www.drugpatentwatch.com/news/enbrel-patent-battle-continues
[4] https://www.drugpatentwatch.com/
[5] https://www.fda.gov/drugs/biosimilars/what-biosimilars-are
[6] https://www.drugpatentwatch.com/drug/enbrel
[7] https://www.law360.com/articles/1731989/amgen-s-enbrel-patent-challenge-loss-stirs-biosimilar-hopes
[8] https://www.enbrel.com/patients/side-effects